Loading
Adding a single course of the bispecific antibody blinatumomab after induction chemotherapy in infants with KMT2A-rearranged leukaemia raised two-year disease-free survival from a historical 49 percent to 82 percent, the first major advance in infant leukaemia in decades.
Single-arm phase 2 study of 30 infants with newly diagnosed KMT2A-rearranged ALL treated on the Interfant-06 backbone with one 28-day course of blinatumomab after induction, compared with historical Interfant-06 controls.
Two-year disease-free survival was 81.6 percent against 49.4 percent historically, overall survival 93.3 versus 65.8 percent, and blinatumomab was well tolerated with no treatment discontinuations for toxicity; measurable residual disease became negative or low in almost all infants.
Blinatumomab after induction is now standard for KMT2A-rearranged infant ALL through the Interfant-21 protocol.
Shares Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year), New England Journal of Medicine.
Shares Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year), Blinatumomab.
Shares Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year), Blinatumomab.
Shares Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year), Blinatumomab.
Shares Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year), Blinatumomab.